Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 3:55 PM ET. This event highlights Entrada's commitment to revolutionizing medicine through its Endosomal Escape Vehicle (EEV^TM) therapeutics, targeting previously inaccessible intracellular diseases. The chat will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days post-event.

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing Endosomal Escape Vehicle (EEV^TM) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat during the Evercore ISI 5^th Annual HealthCONx Virtual Conference on Tuesday, November 29, 2022 at 3:55 p.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD) and ENTR-701 targeting myotonic dystrophy type 1 (DM1).

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.

Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com

FAQ

When is the fireside chat featuring Dipal Doshi from Entrada Therapeutics?

The fireside chat is scheduled for November 29, 2022, at 3:55 PM Eastern Time.

How can I watch the Entrada Therapeutics fireside chat?

The chat will be available via a live webcast on Entrada Therapeutics' investor relations website.

What is the focus of Entrada Therapeutics' EEV therapeutics?

The EEV therapeutics aim to target intracellular diseases that have been considered inaccessible and undruggable.

What diseases are targeted by Entrada Therapeutics' lead oligonucleotide programs?

The lead programs target Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

What is the stock symbol for Entrada Therapeutics?

The stock symbol for Entrada Therapeutics is TRDA.